Cooperativity Between CD8+ T Cells, Non-Neutralizing Antibodies, and Alveolar Macrophages Is Important for Heterosubtypic Influenza Virus Immunity

PLoS Pathogens

Volumn 9, Issue 3, 2013, Pages

  Laidlaw, Brian J ^a,c   Decman, Vilma ^b,d   Ali, Mohammed Alkhatim A ^a   Abt, Michael C ^a   Wolf, Amaya I ^b   Monticelli, Laurel A ^a   Mozdzanowska, Krystyna ^b   Angelosanto, Jill M ^a   Artis, David ^a   Erikson, Jan ^b   Wherry, E John ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CLODRONIC ACID; EPITOPE; FC RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN; GP33-41 EPITOPE; HEMAGGLUTININ; INFLUENZA VACCINE; INTERLEUKIN 15; NON NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; NONSTRUCTURAL PROTEIN 2; POLYMERASE ACIDIC; POLYMERASE BASIC; SIALIDASE; TRANSFERASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN; GLYCOPROTEIN PEPTIDE 33-41, LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NEUTRALIZING ANTIBODY; PEPTIDE FRAGMENT; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; COOPERATION; FLOW CYTOMETRY; H1N1 INFLUENZA PR8 VIRUS; INFLUENZA VIRUS; LUNG ALVEOLUS MACROPHAGE; LUNG FUNCTION; MORBIDITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTECTION; PULSE OXIMETRY; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; VIRUS IMMUNITY; VIRUS LOAD; WEIGHT REDUCTION; ADAPTIVE IMMUNITY; ANIMAL; C57BL MOUSE; CELL LINE; CROSS PROTECTION; DOG; FEMALE; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; INFLUENZA, HUMAN; KNOCKOUT MOUSE; MALE; VIROLOGY;

LYMPHOCYTIC CHORIOMENINGITIS VIRUS; ORTHOMYXOVIRIDAE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CROSS PROTECTION; DOGS; FEMALE; GLYCOPROTEINS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MACROPHAGES, ALVEOLAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; VIRAL LOAD; VIRAL PROTEINS;

EID: 84875992924     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003207     Document Type: Article

References (99)

1. Maines TR, Szretter KJ, Perrone L, Belser JA, Bright RA, et al. (2008) Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev 225: 68-84 doi:10.1111/j.1600-065X.2008.00690.x.
2. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289: 179-186.
3. Centers for Disease Control and Prevention (2010) Estimates of Deaths Associated with Seasonal Influenza - United States, 1976-2007. MMWR 59: 1057-62.
4. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T, et al. (2005) Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437: 1162-1166 doi:10.1038/nature04239.
5. Fauci AS, (2006) Seasonal and pandemic influenza preparedness: science and countermeasures. J Infect Dis 194 Suppl 2: S73-S76 doi:10.1086/507550.
6. Liang S, Mozdzanowska K, Palladino G, Gerhard W, (1994) Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J Immunol 152: 1653-1661.
7. Yewdell JW, Bennink JR, Smith GL, Moss B, (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 1785-1789.
8. Nguyen HH, Moldoveanu Z, Novak MJ, van Ginkel FW, Ban E, et al. (1999) Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 254: 50-60 doi:10.1006/viro.1998.9521.
9. Askonas BA, Taylor PM, Esquivel F, (1988) Cytotoxic T cells in influenza infection. Ann N Y Acad Sci 532: 230-237.
10. Kees U, Krammer PH, (1984) Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J Exp Med 159: 365-377.
11. Braciale TJ, (1977) Immunologic recognition of influenza virus-infected cells. II. Expression of influenza A matrix protein on the infected cell surface and its role in recognition by cross-reactive cytotoxic T cells. J Exp Med 146: 673-689.
12. Tompkins SM, Zhao Z-S, Lo C-Y, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging Infect Dis 13: 426-435 doi:10.3201/eid1303.061125.
13. McMichael AJ, Gotch FM, Noble GR, Beare PA, (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17 doi:10.1056/NEJM198307073090103.
14. Kreijtz JHCM, Bodewes R, van Amerongen G, Kuiken T, Fouchier RAM, et al. (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612-620 doi:10.1016/j.vaccine.2006.08.036.
15. Seo SH, Webster RG, (2001) Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 75: 2516-2525 doi:10.1128/JVI.75.6.2516-2525.2001.
16. Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, et al. (2001) Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211: 143-153 doi:10.1006/cimm.2001.1835.
17. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, et al. (1998) Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72: 5648-5653.
18. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, et al. (1996) Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. J Immunol 156: 3892-3900.
19. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, et al. (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
20. Endo A, Itamura S, Iinuma H, Funahashi S, Shida H, et al. (1991) Homotypic and heterotypic protection against influenza virus infection in mice by recombinant vaccinia virus expressing the haemagglutinin or nucleoprotein of influenza virus. J Gen Virol 72 (Pt 3):: 699-703.
21. Tite JP, Hughes-Jenkins C, O'Callaghan D, Dougan G, Russell SM, et al. (1990) Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection. Immunology 71: 202-207.
22. Wraith DC, Vessey AE, Askonas BA, (1987) Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 68 (Pt 2):: 433-440.
23. He X-S, Holmes TH, Zhang C, Mahmood K, Kemble GW, et al. (2006) Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80: 11756-11766 doi:10.1128/JVI.01460-06.
24. Di Fabio S, Mbawuike IN, Kiyono H, Fujihashi K, Couch RB, et al. (1994) Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-gamma producing CD8+ T cells. Int Immunol 6: 11-19.
25. Epstein SL, (2006) Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 193: 49-53 doi:10.1086/498980.
26. Verbist KC, Cole CJ, Field MB, Klonowski KD, (2011) A role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection. The Journal of Immunology 186: 174-182 doi:10.4049/jimmunol.1002613.
27. Kedzierska K, Stambas J, Jenkins MR, Keating R, Turner SJ, et al. (2007) Location rather than CD62L phenotype is critical in the early establishment of influenza-specific CD8+ T cell memory. Proc Natl Acad Sci USA 104: 9782-9787 doi:10.1073/pnas.0703699104.
28. Ely KH, Cookenham T, Roberts AD, Woodland DL, (2006) Memory T cell populations in the lung airways are maintained by continual recruitment. J Immunol 176: 537-543.
29. Hogan RJ, Usherwood EJ, Zhong W, Roberts AA, Dutton RW, et al. (2001) Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. J Immunol 166: 1813-1822.
30. Price GE, Soboleski MR, Lo C-Y, Misplon JA, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 5: e13162 doi:10.1371/journal.pone.0013162.
31. Lamere MW, Lam H-T, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. The Journal of Immunology 186: 4331-4339 doi:10.4049/jimmunol.1003057.
32. Lamere MW, Moquin A, Lee FE-H, Misra RS, Blair PJ, et al. (2011) Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 85: 5027-5035 doi:10.1128/JVI.00150-11.
33. Rangel-Moreno J, Carragher DM, Misra RS, Kusser K, Hartson L, et al. (2008) B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol 180: 454-463.
34. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. The Journal of Immunology 181: 4168-4176.
35. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrançois L, et al. (2011) Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 187: 5510-5514 doi:10.4049/jimmunol.1102243.
36. McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, et al. (2012) Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Invest 122: 2847-2856 doi:10.1172/JCI63689.
37. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, et al. (2011) Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS ONE 6: e16245 doi:10.1371/journal.pone.0016245.
38. Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280 doi:10.1038/nm.2612.
39. Mueller SN, Langley WA, Li G, García-Sastre A, Webby RJ, et al. (2010) Qualitatively different memory CD8+ T cells are generated after lymphocytic choriomeningitis virus and influenza virus infections. The Journal of Immunology 185: 2182-2190 doi:10.4049/jimmunol.1001142.
40. Decman V, Laidlaw BJ, Dimenna LJ, Abdulla S, Mozdzanowska K, et al. (2010) Cell-intrinsic defects in the proliferative response of antiviral memory CD8 T cells in aged mice upon secondary infection. J Immunol 184: 5151-5159 doi:10.4049/jimmunol.0902063.
41. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, Ho JH, et al. (2011) Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 108: 5354-5359 doi:10.1073/pnas.1019378108.
42. Lee BO, Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Makris M, et al. (2005) CD4 T cell-independent antibody response promotes resolution of primary influenza infection and helps to prevent reinfection. J Immunol 175: 5827-5838.
43. Johansson BE, Kilbourne ED, (1990) Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections. J Infect Dis 162: 800-809.
44. Johansson BE, Bucher DJ, Kilbourne ED, (1989) Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 63: 1239-1246.
45. Epstein SL, Price GE, (2010) Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 9: 1325-1341 doi:10.1586/erv.10.123.
46. Lambe T, (2012) Novel viral vectored vaccines for the prevention of influenza. Mol Med 18: 1153-1160 doi:10.2119/molmed.2012.00147.
47. Bodewes R, Kreijtz JHCM, Hillaire MLB, Geelhoed-Mieras MM, Fouchier RAM, et al. (2010) Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J Gen Virol 91: 1743-1753 doi:10.1099/vir.0.020784-0.
48. Matloubian M, Concepcion RJ, Ahmed R, (1994) CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol 68: 8056-8063.
49. Nolz JC, Harty JT, (2011) Protective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infection. Immunity 34: 781-793 doi:10.1016/j.immuni.2011.03.020.
50. Jabbari A, Harty JT, (2006) Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype. J Exp Med 203: 919-932 doi:10.1084/jem.20052237.
51. Topham DJ, Doherty PC, (1998) Clearance of an influenza A virus by CD4+ T cells is inefficient in the absence of B cells. J Virol 72: 882-885.
52. Allan W, Tabi Z, Cleary A, Doherty PC, (1990) Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J Immunol 144: 3980-3986.
53. Kitamura D, Roes J, Kühn R, Rajewsky K, (1991) A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350: 423-426 doi:10.1038/350423a0.
54. Mason DY, Jones M, Goodnow CC, (1992) Development and follicular localization of tolerant B lymphocytes in lysozyme/anti-lysozyme IgM/IgD transgenic mice. Int Immunol 4: 163-175.
55. Renegar KB, Small PA, Boykins LG, Wright PF, (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: 1978-1986.
56. McGill J, van Rooijen N, Legge KL, (2010) IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. Journal of Experimental Medicine 207: 521-534 doi:10.1084/jem.20091711.
57. Becker TC, Wherry EJ, Boone D, Murali-Krishna K, Antia R, et al. (2002) Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195: 1541-1548.
58. Castillo EF, Stonier SW, Frasca L, Schluns KS, (2009) Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. The Journal of Immunology 183: 4948-4956 doi:10.4049/jimmunol.0900719.
59. Verbist KC, Field MB, Klonowski KD, (2011) Cutting edge: IL-15-independent maintenance of mucosally generated memory CD8 T cells. The Journal of Immunology 186: 6667-6671 doi:10.4049/jimmunol.1004022.
60. Wrammert J, Koutsonanos D, Li G-M, Edupuganti S, Sui J, et al. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Journal of Experimental Medicine 208: 181-193 doi:10.1084/jem.20101352.
61. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, et al. (2009) Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 5: e1000350 doi:10.1371/journal.ppat.1000350.
62. Wei C-J, Boyington JC, McTamney PM, Kong W-P, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064 doi:10.1126/science.1192517.
63. Sui J, Hwang WC, Perez S, Wei G, Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273 doi:10.1038/nsmb.1566.
64. Li G-M, Chiu C, Wrammert J, McCausland M, Andrews SF, et al. (2012) Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci USA 109: 9047-9052 doi:10.1073/pnas.1118979109.
65. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, et al. (1999) Human infection with influenza H9N2. Lancet 354: 916-917.
66. Schotsaert M, De Filette M, Fiers W, Saelens X, (2009) Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 8: 499-508 doi:10.1586/erv.09.6.
67. Gerhard W, Mozdzanowska K, Zharikova D, (2006) Prospects for universal influenza virus vaccine. Emerging Infect Dis 12: 569-574 doi:10.3201/eid1204.051020.
68. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163 doi:10.1038/13484.
69. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W, (2005) Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79: 6644-6654 doi:10.1128/JVI.79.11.6644-6654.2005.
70. Mozdzanowska K, Maiese K, Furchner M, Gerhard W, (1999) Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254: 138-146 doi:10.1006/viro.1998.9534.
71. Bakkouri El K, Descamps F, De Filette M, Smet A, Festjens E, et al. (2011) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. The Journal of Immunology 186: 1022-1031 doi:10.4049/jimmunol.0902147.
72. Jegerlehner A, Schmitz N, Storni T, Bachmann MF, (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605.
73. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW, (2001) Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166: 7381-7388.
74. Fu T-M, Freed DC, Horton MS, Fan J, Citron MP, et al. (2009) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385: 218-226 doi:10.1016/j.virol.2008.11.035.
75. Jayasekera JP, Moseman EA, Carroll MC, (2007) Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 81: 3487-3494 doi:10.1128/JVI.02128-06.
76. Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF, (2002) Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 8: 373-378 doi:10.1038/nm0402-373.
77. S Reis E, Falcão DA, Isaac L, (2006) Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol 63: 155-168 doi:10.1111/j.1365-3083.2006.01729.x.
78. Thepen T, van Rooijen N, Kraal G, (1989) Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med 170: 499-509.
79. van Rooijen N, Sanders A, (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
80. Nénan S, Boichot E, Planquois J-M, Berna P, Hitier S, et al. (2008) Effects of depletion of neutrophils or macrophages on the inflammatory response induced by metalloelastase (MMP-12) in mice airways. Eur J Pharmacol 579: 374-381 doi:10.1016/j.ejphar.2007.10.048.
81. Goodwin K, Viboud C, Simonsen L, (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159-1169 doi:10.1016/j.vaccine.2005.08.105.
82. Osterholm MT, Kelley NS, Sommer A, Belongia EA, (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36-44 doi:10.1016/S1473-3099(11)70295-X.
83. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E, (2007) Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357: 1373-1381 doi:10.1056/NEJMoa070844.
84. van Duin D, Shaw AC, (2007) Toll-like receptors in older adults. J Am Geriatr Soc 55: 1438-1444 doi:10.1111/j.1532-5415.2007.01300.x.
85. Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, et al. (2006) Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev 211: 81-92 doi:10.1111/j.0105-2896.2006.00382.x.
86. Stout-Delgado HW, Yang X, Walker WE, Tesar BM, Goldstein DR, (2008) Aging impairs IFN regulatory factor 7 up-regulation in plasmacytoid dendritic cells during TLR9 activation. The Journal of Immunology 181: 6747-6756.
87. Decman V, Laidlaw BJ, Doering TA, Leng J, Ertl HCJ, et al. (2012) Defective CD8 T cell responses in aged mice are due to quantitative and qualitative changes in virus-specific precursors. J Immunol 188: 1933-1941 doi:10.4049/jimmunol.1101098.
88. Yager EJ, Ahmed M, Lanzer K, Randall TD, Woodland DL, et al. (2008) Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. Journal of Experimental Medicine 205: 711-723 doi:10.1084/jem.20071140.
89. Panda A, Arjona A, Sapey E, Bai F, Fikrig E, et al. (2009) Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol 30: 325-333 doi:10.1016/j.it.2009.05.004.
90. Grubeck-Loebenstein B, Bella Della S, Iorio AM, Michel J-P, Pawelec G, et al. (2009) Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 21: 201-209.
91. Kumar R, Burns EA, (2008) Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 7: 467-479 doi:10.1586/14760584.7.4.467.
92. Fülöp T, Fóris G, Wórum I, Leövey A, (1985) Age-dependent alterations of Fc gamma receptor-mediated effector functions of human polymorphonuclear leucocytes. Clin Exp Immunol 61: 425-432.
93. Amanna IJ, Carlson NE, Slifka MK, (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357: 1903-1915 doi:10.1056/NEJMoa066092.
94. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, et al. (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9: 1131-1137 doi:10.1038/nm917.
95. Roberts AD, Ely KH, Woodland DL, (2005) Differential contributions of central and effector memory T cells to recall responses. J Exp Med 202: 123-133 doi:10.1084/jem.20050137.
96. McKinstry KK, Strutt TM, Swain SL, (2011) Hallmarks of CD4 T cell immunity against influenza. J Intern Med 269: 507-518 doi:10.1111/j.1365-2796.2011.02367.x.
97. Teijaro JR, Verhoeven D, Page CA, Turner D, Farber DL, (2010) Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 84: 9217-9226 doi:10.1128/JVI.01069-10.
98. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R, (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77: 4911-4927.
99. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, et al. (2011) Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7 doi:10.1093/cid/ciq015.